BRCA2 and cancer: In particular, tumors with BRCA2 pathogenic variants associated with defective HR are sensitive to Poly(ADP ribose) polymerase inhibitors, the efficacy of which is mediated through synthetic lethality with BRCA2 loss-of-function in cancer cells [80,81].